Study S003309

A 52-week Double-blind, Randomized, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of SAR425899 for the Treatment of Non-alcoholic Steatohepatitis (NASH)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03437720
Acronym: Restore
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: WITHDRAWN
Enrollment: 0
Start: 2019-05-23
Primary completion: 2021-08-25
Lead sponsor: Sanofi
Conditions: Non-alcoholic Steatohepatitis; Type 2 Diabetes Mellitus
Interventions: DRUG:SAR425899; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: EUDRACT_NUMBER:2017-002371-26; OTHER:U1111-1191-5486; NIH:2017

Registered primary outcomes

Resolution of Non-alcoholic steatohepatitis (NASH) [Week 52]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.